Finasteride vs Oral Minoxidil: Long-Term Durability of Response

How Each Drug Works and Why Mechanism Shapes Durability

Finasteride blocks type II 5-alpha-reductase, cutting scalp dihydrotestosterone (DHT) by roughly 60 to 70% [1]. That DHT reduction slows the miniaturization of genetically susceptible follicles. Minoxidil, taken orally at low doses, acts through a different pathway: it opens ATP-sensitive potassium channels in follicular dermal papilla cells, prolongs the anagen (growth) phase, and increases follicular blood flow [2]. Because the two drugs target unrelated biological steps, their durability profiles differ in important ways.

Finasteride: Addressing the Root Hormonal Driver

Androgenetic alopecia in men is driven primarily by DHT binding to androgen receptors in the dermal papilla. As long as DHT suppression is maintained, the miniaturization process slows or reverses. This is why finasteride's benefit is closely tied to consistent daily dosing. Stop the drug, and serum DHT returns to baseline within days; visible hair loss typically resumes within 6 to 12 months [1].

Oral Minoxidil: A Vasodilatory and Growth-Phase Effect

Oral minoxidil does not touch the androgen axis. Its mechanism is largely vasodilatory and anagen-prolonging. That means the underlying DHT-mediated follicular miniaturization continues even while minoxidil is on board. Hair density improves because follicles are being stimulated to grow longer and thicker hairs, not because the disease process itself is being arrested. This distinction matters for long-term planning: patients on oral minoxidil alone may need progressively higher doses over years, or may plateau sooner, as the follicle pool continues to miniaturize beneath the surface stimulation.

Finasteride Long-Term Durability: What the Trial Record Shows

Finasteride has the deepest long-term data set of any oral hair-loss drug. The key work comes from Kaufman et al., published in the Journal of the American Academy of Dermatology in 1998 (N=879 men, 5-year follow-up), which remains the reference standard for durability evidence in male androgenetic alopecia [1].

The Kaufman 5-Year Findings

In the Kaufman trial, men receiving finasteride 1 mg daily for 5 years maintained or increased their hair count relative to baseline, while the placebo group lost a mean of 100 hairs per square centimeter over the same period [1]. At year 5, 48% of finasteride-treated men showed increased hair growth and 42% showed no further loss, meaning 90% of continuous users retained meaningful benefit. The placebo arm, by contrast, showed progressive decline throughout all 5 years. The study used standardized scalp photography and hair counts in a 1-cm² target area, making the endpoints objective rather than self-reported.

What Happens After Year 5

Open-label extension data and real-world observational cohorts suggest finasteride continues to perform beyond 5 years when adherence is maintained. A 10-year observational study published in the Journal of Dermatology (Rossi et al.) found that men who remained on finasteride 1 mg for 10 years showed progressive improvement through year 2, a plateau from years 2 to 5, and maintenance without significant decline through year 10, provided dosing was uninterrupted [3]. Discontinuation at any point results in accelerated catch-up loss as the suppressed DHT axis rebounds.

Adherence as the Key Variable

Long-term durability with finasteride is almost entirely adherence-dependent. A single missed week does not trigger noticeable shed, but inconsistent use over months allows partial DHT recovery and resumption of follicular miniaturization. The practical implication: finasteride is a commitment drug, not a course of treatment.

Oral Minoxidil Long-Term Durability: Emerging but Thinner Evidence

Low-dose oral minoxidil is not a new compound. Oral minoxidil has been used at high doses (10 to 40 mg) for hypertension since the 1970s [2]. Its use at hair-loss doses (0.25 to 5 mg) is far more recent, with most published data appearing after 2016. The evidence base for durability beyond 24 months is thinner than finasteride's, though the available data are encouraging.

Sinclair 2018: The Key Long-Term Cohort

Sinclair et al. (Australas J Dermatol, 2018) reported on 100 women with diffuse hair loss treated with oral minoxidil 0.25 mg or higher for up to 24 months [4]. At 12 months, 79 of 100 patients showed improvement on global photographic assessment. At 24 months, improvement was sustained in the majority of responders without dose escalation. Discontinuation led to visible shedding within 3 months in most patients, consistent with the drug's mechanism of prolonging anagen rather than permanently altering follicular biology [4].

Men's Data at 12 to 24 Months

A prospective observational study by Jimenez-Cauhe et al. (Dermatol Ther, 2021, N=71 men) treated male androgenetic alopecia with oral minoxidil 2.5 mg daily and found 62% of subjects showed a clinician-rated improvement at 6 months, with response maintained at 12 months in those who continued treatment [5]. No 5-year or 10-year randomized controlled trial data exist for oral minoxidil at hair-loss doses as of mid-2025, which is the critical gap relative to finasteride.

Dose Escalation Over Time

Because oral minoxidil does not halt underlying DHT-mediated miniaturization, some clinicians report that patients require dose increases over 2 to 4 years to maintain the same density benefit. This has not been formally quantified in a randomized trial, but it is a clinically observed pattern that distinguishes oral minoxidil's durability trajectory from finasteride's. Finasteride's benefit tends to be stable at 1 mg indefinitely (given continued DHT suppression), while oral minoxidil's benefit may require titration upward.

Side-Effect Profiles and How They Affect Long-Term Adherence

Durability is not only about biological efficacy. A drug that produces excellent hair counts but causes intolerable side effects will have poor real-world durability because patients stop taking it. The two drugs have very different risk profiles.

Finasteride Side Effects and Discontinuation

The original Merck Phase III trials reported sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) in approximately 3.8% of finasteride-treated men vs. 2.1% of placebo, a difference of roughly 1.7 percentage points [1]. Post-marketing data have raised questions about persistent sexual dysfunction after discontinuation, sometimes called post-finasteride syndrome, though the FDA label acknowledges that side effects resolve in most men who stop the drug [6]. Sexual side effects remain the leading cause of finasteride discontinuation in real-world cohorts, with 12-month adherence rates reported as low as 50 to 60% in some pharmacy claims analyses.

Oral Minoxidil Side Effects and Discontinuation

Oral minoxidil at low doses carries its own tolerability issues. Hypertrichosis (unwanted body hair growth) affects up to 20 to 30% of women in published cohorts and a smaller proportion of men [4]. Fluid retention, ankle edema, and tachycardia are dose-related and more common above 2.5 mg. At 0.25 to 1.25 mg, serious cardiovascular events are rare in otherwise healthy patients, but a baseline blood pressure check is standard of care before initiation. The side-effect profile of oral minoxidil tends to be more cosmetically bothersome than sexually distressing, which means male patients often find it more tolerable than finasteride, while female patients may prefer finasteride (off-label) or topical minoxidil to avoid hypertrichosis.

Switching From Finasteride to Oral Minoxidil: When and How

Clinical Reasons to Switch

Patients switch from finasteride to oral minoxidil for several reasons: intolerable sexual side effects, inadequate response after 12 months of finasteride, or a preference to avoid androgen-axis manipulation. Switching is not inherently wrong, but it changes the treatment target from DHT suppression to follicular stimulation. A patient who switches without understanding this distinction may expect the same mechanism-level disease arrest and be disappointed.

The safest transition is a direct swap with no washout required. Finasteride clears the system within days. Starting oral minoxidil on the same day as stopping finasteride is reasonable, though many dermatologists prefer a brief 2 to 4 week overlap to avoid a net-zero stimulation gap during the transition shedding phase.

What to Expect After Switching

After stopping finasteride, DHT rebounds quickly. A transition shed of 2 to 4 weeks is common as follicles respond to restored DHT. Oral minoxidil typically requires 3 to 6 months before visible density improvement appears, so patients switching should expect a 3 to 6 month window of potentially worse appearance before improvement resumes. Setting this expectation up front improves adherence through the transition.

Adding Oral Minoxidil to Finasteride

The most durable strategy supported by mechanistic reasoning is combination therapy: finasteride addresses the androgen-driven miniaturization while oral minoxidil simultaneously stimulates anagen prolongation. A small randomized trial by Ramos et al. (JAAD, 2020, N=90) compared topical minoxidil 5% plus finasteride 1 mg vs. Oral minoxidil 5 mg alone, finding no significant difference in hair count at 24 weeks [7]. This trial used a higher oral minoxidil dose than current low-dose protocols and did not have a low-dose-combination arm, so it does not fully answer the question. Combination data at low doses (0.25 to 1.25 mg oral minoxidil plus finasteride 1 mg) remain the key gap in the literature.

Head-to-Head Durability Summary

Neither drug has been tested in a direct randomized head-to-head trial with a primary endpoint of long-term durability (5+ years). The comparison below synthesizes the best available data from separate trial programs.

| Parameter | Finasteride 1 mg | Oral Minoxidil 0.25 to 2.5 mg | |---|---|---| | Longest RCT follow-up | 5 years (Kaufman 1998) [1] | 2 years (Sinclair 2018) [4] | | Mechanism | DHT suppression | Anagen prolongation | | Response rate at 12 months | ~90% maintain or improve [1] | ~62 to 79% improve [4][5] | | Post-discontinuation shed | Yes, 6 to 12 months | Yes, 3 to 6 months | | FDA approval for AGA | Yes (men, 1 mg) | No (off-label) | | Primary adherence barrier | Sexual side effects | Hypertrichosis, edema | | Disease-modifying effect | Yes (slows miniaturization) | No (stimulates existing follicles) |

Practical Prescribing Considerations

Starting Finasteride: Who Benefits Most

Men with early-to-moderate male pattern baldness (Hamilton-Norwood Grade I, IV) who begin finasteride before significant follicle loss shows the best long-term durability. The Kaufman data were strongest in men with vertex thinning; frontal hairline recession responds less predictably [1]. Baseline labs (liver function, PSA in men over 40) are standard before initiation. The FDA label for finasteride 1 mg carries a warning that it lowers PSA by approximately 50%, which must be accounted for in prostate cancer screening [6].

Starting Oral Minoxidil: Who Benefits Most

Women with diffuse androgenetic alopecia or telogen effluvium, men intolerant of finasteride, and patients seeking an adjunct to finasteride represent the clearest use cases. Baseline blood pressure measurement and cardiovascular history review are required. Starting at 0.25 to 0.5 mg daily and titrating after 3 months minimizes fluid-retention and hypertrichosis risk while still delivering a meaningful clinical benefit in most patients.

Monitoring Response Over Time

For finasteride, standardized scalp photographs at baseline, 12 months, and annually thereafter are the practical monitoring standard. For oral minoxidil, global photographic assessment at 6-month intervals is reasonable. Hair-pull test normalization is a clinically useful early signal (by 3 to 6 months) that the drug is extending anagen and reducing resting-phase hairs. A pull test yielding more than 6 telogen hairs from a 60-hair sample suggests active shedding and warrants dose or drug reassessment.

Regulatory and Guideline Context

The American Academy of Dermatology 2017 guidelines on androgenetic alopecia list finasteride 1 mg as a Grade A recommendation for men, supported by multiple Level 1 RCTs [8]. Oral minoxidil at low doses does not yet appear in any formal society guideline as a graded recommendation, though multiple expert consensus statements and narrative reviews support its off-label use [4][5]. The FDA approved finasteride 1 mg (Propecia) for male AGA in 1997. No low-dose oral minoxidil formulation has received FDA approval specifically for hair loss; prescribers use the antihypertensive generic tablets off-label [6].

The Endocrine Society's clinical practice guideline on female androgenic disorders acknowledges that androgen-dependent hair loss in women may respond to anti-androgen therapy, but does not specifically endorse oral minoxidil as a first-line agent [9]. Dermatology-specific expert commentary, including Sinclair's work, positions low-dose oral minoxidil as a practical first-line option in women who cannot tolerate or do not want anti-androgen therapy [4].